Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
89.30
-2.00 (-2.19%)
Feb 21, 2025, 1:48 PM CST
-48.83%
Market Cap 12.75B
Revenue (ttm) 972.97M
Net Income (ttm) 452.32M
Shares Out 141.20M
EPS (ttm) 3.24
PE Ratio 27.85
Forward PE 5.65
Dividend 1.00 (1.11%)
Ex-Dividend Date n/a
Volume 580,581
Average Volume 580,282
Open 91.90
Previous Close 91.30
Day's Range 87.80 - 91.90
52-Week Range 49.90 - 196.00
Beta 1.26
RSI 75.09
Earnings Date Apr 2, 2025

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; HND-033 and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and h... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.